A Network of Discovery
BERG's therapeutic research and development begins with the patient. Using the patient's own biological samples we can examine the molecular activity of both healthy and diseased cellular environments. With adaptive omic molecular data we can study the biological systems and interrogate the differentials using proprietary machine learning algorithms (AI). This combination of systems biology and artificial Intelligence is the BERG Interrogative Biology® platform. With the network models derived from our platform, we are able to drive drug discovery by translating biological output into therapeutic candidates and improved diagnostics.
The platform analyzes trillions of data points sampled from patient biology and clinical information. The BERG Interrogative Biology® platform examines all of the data in an unbiased way with multiple iterations looking deep into the data to create network models of the patients biological activity at a molecular level.
From these network models we can discover novel biological points of interests. These biomarkers can lead to potential drug targets to develop therapeutics, or an indicator of disease that can be developed into improved diagnostics for the patient.
Starting with patient biology is the key to our network of discovery.
Cancer Metabolism and BPM 31510
BPM 31510 is BERG's lead molecule currently in phase I and II trials. Its development and clinical trials have been guided by the BERG Interrogative Biology® platform. BPM 31510 is being applied to both topical and solid tumor forms of cancer.
When a cell becomes cancerous it's metabolism is altered changing the internal molecular mechanisms of the cell. When a healthy cell becomes damaged these mechanisms can activate the process of apoptosis or cell death which removes the damaged cell from the body. But in a cancerous cell these alterations disable the process of apoptosis allowing the cancer cell to cheat death and leading to the formation of tumors.
BPM 31510 restores the metabolism of cancerous cells which reactivates the molecular mechanisms that detect cell damage and trigger the process of apoptosis or cell death. The cancer cells die and are removed from the body through this natural process.
Chemotherapy induced Alopecia and BPM 31543
BPM 31543 is a first-in-class topical compound currently in a Phase 1 clinical trial for the treatment of chemotherapy induced alopecia. We are currently enrolling patients at both the Memorial Sloan Kettering Cancer Center and Cedars-Sinai Medical Center.
Neurology - Discovery program
BERG is actively applying our Interrogative Biology® platform in the pursuit of novel therapeutic targets for Alzheimer's and Parkinson's disease. Working with our partners at Icahn School of Medicine at Mount Sinai and the Parkinson's Institute and Clinical Center we aim to utilize our platform to examine the clinical patient population in an unbiased way, stratifying the population and discovering novel indicators of the CNS diseases.
Metabolic Disease - Discovery program
Through the use of the Interrogative Biology® platform BERG is pursuing the discovery of novel drivers of metabolic disease. This has led to the identification of first in class molecules that have progressed beyond the proof of concept stage. Our molecules achieve similar results to current therapies, but operate using a different method of action which may also have the potential to provide additional benefits to patients. Our personalized medicine approach enables the identification of biomarkers for patient stratification that will guide our clinical development path.